The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

FCS manifests through a spectrum of symptoms, including eruptive xanthomas, lipemia retinalis, abdominal pain, hepatosplenomegaly, and neurological manifestations, such as irritability, memory loss, ...

Suzhou Ribo Life Sciences (Ribo) is a drug development company that develops nucleic acid drugs and related products based on the RNA interference (RNAi) technology. The company’s pipeline products ...

The Food and Drug Administration (FDA) has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). In FCS, mutations in ...

Zodasiran is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). According to GlobalData, Phase II drugs ...